126110-92-7

Basic information

• Product Name: (2S,3aS,7aS)-1-((S)-6-Benzyloxycarbonylamino-2-hydroxy-hexanoyl)-octahydro-indole-2-carboxylic acid ethyl ester
• Synonyms: (2S,3aS,7aS)-1-((S)-6-Benzyloxycarbonylamino-2-hydroxy-hexanoyl)-octahydro-indole-2-carboxylic acid ethyl ester
• CAS NO: 126110-92-7
• Molecular Weight: 460.571
• Mol File: 126110-92-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,3aS,7aS)-1-((S)-6-Benzyloxycarbonylamino-2-hydroxy-hexanoyl)-octahydro-indole-2-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3aS,7aS)-1-((S)-6-Benzyloxycarbonylamino-2-hydroxy-hexanoyl)-octahydro-indole-2-carboxylic acid ethyl ester(126110-92-7)
• EPA Substance Registry System: (2S,3aS,7aS)-1-((S)-6-Benzyloxycarbonylamino-2-hydroxy-hexanoyl)-octahydro-indole-2-carboxylic acid ethyl ester(126110-92-7)

Safety Data

• Hazardous Substances Data: 126110-92-7(Hazardous Substances Data)

Upstream product

• 59221-35-1 (S)-6-[[(Phenylmethoxy)carbonyl]amino]-2-hydroxyhexanoic acid 
• 82864-25-3 ethyl (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride 

Downstream Products

• 126110-69-8 (2S,3aS,7aS)-1-{(S)-6-Benzyloxycarbonylamino-2-[hydroxy-(4-phenyl-butyl)-phosphinoyloxy]-hexanoyl}-octahydro-indole-2-carboxylic acid ethyl ester 
• 126110-40-5 (2S,3aS,7aS)-1-{(S)-6-Amino-2-[hydroxy-(4-phenyl-butyl)-phosphinoyloxy]-hexanoyl}-octahydro-indole-2-carboxylic acid 

Relevant articles and documents

(Phosphinyloxy)acid amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogues of (S)-1-[6-Amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]- L-proline

Analogues of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]- L-proline (1, SQ 29,852) in which the terminal proline residue has been replaced by a variety of substituted and heteroatom-substituted prolines, N-arylglycines, N-cycloalkylglycines, and bicyclic amino acids have been synthesized and evaluated as inhibitors of angiotensin converting enzyme in vitro an in vivo. In general, the addition of lipophilic substituents to the 4-position of proline of the parent phosphate 1 resulted in substantial increases in vitro activity. The largest improvements were observed in the case of cis-benzyl (36-fold) and dithioketal (24-fold) analogues 2r and 2x, respectively. These enhancements of in vitro activity were accompanied by modest increases (2-3.5-fold) in in vivo (iv) activity. Among the various terminal amino acid replacements examined in this study, the indoline-based analogue 2i was by far the most potent compound on iv administration in the normotensive rat.